-
1.发明授权Canine tumor cell and allogeneic dendritic cell fused vaccine and method for preparing the same 有权犬肿瘤细胞和同种异体树突细胞融合疫苗及其制备方法公开(公告)号：US08778361B2
公开(公告)日：2014-07-15
申请号：US12483735
申请日：2009-06-12
Applicant: Rea-Min Chu , Chien-Chun Pai , Tien-Fu Chuang
Inventor： Rea-Min Chu , Chien-Chun Pai , Tien-Fu Chuang
CPC classification number: C12N5/16 , A61K39/001 , A61K39/0011 , A61K2039/5152 , A61K2039/5154
Abstract: The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived dendritic cells and canine tumor cells. The canine immune system can be induced to produce tumor specific T lymphocytes and natural killer cells when the fusion cells used as a vaccine is injected into a canine body.
Abstract translation: 本发明提供了通过融合犬肿瘤细胞和同种异体树突状细胞的基于树突状细胞的疫苗及其制备方法。 通过融合犬骨髓来源的树突状细胞和犬肿瘤细胞产生表达犬肿瘤抗原的融合细胞。 当用作疫苗的融合细胞注射到犬体内时，可以诱导犬免疫系统产生肿瘤特异性T淋巴细胞和天然杀伤细胞。
-
公开(公告)号：US20110275081A1
公开(公告)日：2011-11-10
申请号：US12953855
申请日：2010-11-24
Applicant: Rea-Min Chu , Han-Jung Lei , Yi-Lun Chiang
Inventor： Rea-Min Chu , Han-Jung Lei , Yi-Lun Chiang
CPC classification number: C12Q1/6888 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
Abstract: The present invention is related to a biomarker for diagnosis of canine cancer, wherein the biomarker is KMO (kynureinie 3-monooxygenase) gene, and the canine cancers including CTVT (canine transmissible venereal tumor) and MGT (mammary gland tumor). The expression level of KMO gene in canine malignant tumor tissues is up-regulated as compared with benign tissues. Furthermore, the expression level of KMO gene in malignant tumor tissue is higher than in the non-metastasis tumor tissue. By detection of the expression level of the present invention biomarker in suspecting tissue specimen, malignancy of tumor tissues can be determined correctly and rapidly.
Abstract translation: 本发明涉及用于诊断犬癌的生物标志物，其中生物标志物是KMO（kynereinie 3-monooxygenase）基因，以及包括CTVT（犬传染性病毒性肿瘤）和MGT（乳腺肿瘤））的犬癌。 与良性组织相比，犬恶性肿瘤组织中KMO基因的表达水平上调。 此外，恶性肿瘤组织中KMO基因的表达水平高于非转移性肿瘤组织。 通过检测可疑组织标本中本发明生物标志物的表达水平，可以正确，快速地确定肿瘤组织的恶性。
-
公开(公告)号：US20090073420A1
公开(公告)日：2009-03-19
申请号：US12076203
申请日：2008-03-14
Applicant: Chii-Wann Lin , Jheng-Long Lee , Rong-Huay Juang , Shi-Ming Lin , Chih-Kung Lee , Rea-Min Chu , Ching-Ho Wang , Jim-Min Fang , Tsung-Liang Chuang
Inventor： Chii-Wann Lin , Jheng-Long Lee , Rong-Huay Juang , Shi-Ming Lin , Chih-Kung Lee , Rea-Min Chu , Ching-Ho Wang , Jim-Min Fang , Tsung-Liang Chuang
IPC: G01N21/00
CPC classification number: G01N21/553
Abstract: An optical waveguide SPR sensor is adapted for differential measurement. The optical waveguide SPR sensor includes a base, a bottom layer, and at least one set of optical waveguide layers. The set of the optical waveguide layers includes a measuring optical waveguide channel and a reference optical waveguide channel. The measuring optical waveguide channel includes an SPR sensing film layer. The measuring optical waveguide channel and the reference optical waveguide channel are independently configured and substantially parallel one to another. The bottom layer has a refractive index higher than a refractive index of the optical waveguide layer.
Abstract translation: 光波导SPR传感器适用于差分测量。 光波导SPR传感器包括基底，底层以及至少一组光波导层。 该组光波导层包括测量光波导通道和参考光波导通道。 测量光波导通道包括SPR感测膜层。 测量光波导通道和参考光波导通道独立地构造并基本上彼此平行。 底层的折射率高于光波导层的折射率。
-
Patent Agency Ranking
公开(公告)号：US07323450B2
公开(公告)日：2008-01-29
申请号：US10798096
申请日：2004-03-11
Applicant: Rea-Min Chu , Ching-Yi Lin , Ya-Wen Hsiao , Kuang-Wen Liao
Inventor： Rea-Min Chu , Ching-Yi Lin , Ya-Wen Hsiao , Kuang-Wen Liao
CPC classification number: A61K48/005 , A61K38/204 , A61K38/2086 , C07K14/5412 , C07K14/5443 , A61K2300/00
Abstract: Disclosed is a complex immuno-gene medical composition for activating NK cells to enhance a host immune system. The composition includes a plurality of cytokines, including Th1 and Th2 cytokines. Th2 cytokines antagonize TGF-β inhibiting NK cells to disable the inhibition of the immune system. Th1 cytokines activate NK cells in a host to enhance the host's ability to fight against tumor cells. By use of the complex immuno-gene medical composition, removal of tumor cells is expected.
Abstract translation: 公开了用于激活NK细胞以增强宿主免疫系统的复合免疫基因医药组合物。 该组合物包括多种细胞因子，包括Th1和Th2细胞因子。 Th2细胞因子拮抗TGF-β抑制NK细胞以阻止免疫系统的抑制。 Th1细胞因子激活宿主中的NK细胞，以增强宿主对抗肿瘤细胞的能力。 通过使用复合免疫基因医药组合物，预期可以去除肿瘤细胞。
-
公开(公告)号：US20050203037A1
公开(公告)日：2005-09-15
申请号：US10798096
申请日：2004-03-11
Applicant: Rea-Min Chu , Ching-Yi Lin , Ya-Wen Hsiao , Kuang-Wen Liao
Inventor： Rea-Min Chu , Ching-Yi Lin , Ya-Wen Hsiao , Kuang-Wen Liao
IPC: A61K48/00
CPC classification number: A61K48/005 , A61K38/204 , A61K38/2086 , C07K14/5412 , C07K14/5443 , A61K2300/00
Abstract: Disclosed is a complex immuno-gene medical composition activating NK cells to enhance host immune system. The composition is usage of a combination of a plurality of cytokines, combined usage of the kinds of Th1 and Th2 cytokines. Th2 cytokine antagonizes TGF-β inhibiting NK cells to disable the inhibition of immune system, and Th1 cytokine activates NK cells in host to enhance the ability fighting against tumor cells. By means of the complex immuno-gene medical composition, removal of tumor cells is expectable.
Abstract translation: 公开了激活NK细胞以增强宿主免疫系统的复杂的免疫基因医学组合物。 该组合物是多种细胞因子的组合的使用，Th1和Th2种类的细胞因子的组合使用。 Th2细胞因子拮抗TGF-β抑制NK细胞，免除免疫系统的抑制，Th1细胞因子激活宿主NK细胞，增强抗肿瘤细胞的能力。 通过复合免疫基因医学组合物，可以预期去除肿瘤细胞。
-
公开(公告)号：US08642267B2
公开(公告)日：2014-02-04
申请号：US12953855
申请日：2010-11-24
Applicant: Rea-Min Chu , Han-Jung Lei , Yi-Lun Chiang
Inventor： Rea-Min Chu , Han-Jung Lei , Yi-Lun Chiang
IPC: C12Q1/68
CPC classification number: C12Q1/6888 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
Abstract: The present invention is related to a biomarker for diagnosis of canine cancer, wherein the biomarker is KMO (kynureinie 3-monooxygenase) gene, and the canine cancers including CTVT (canine transmissible venereal tumor) and MGT (mammary gland tumor). The expression level of KMO gene in canine malignant tumor tissues is up-regulated as compared with benign tissues. Furthermore, the expression level of KMO gene in malignant tumor tissue is higher than in the non-metastasis tumor tissue. By detection of the expression level of the present invention biomarker in suspecting tissue specimen, malignancy of tumor tissues can be determined correctly and rapidly.
Abstract translation: 本发明涉及用于诊断犬癌的生物标志物，其中生物标志物是KMO（kynereinie 3-monooxygenase）基因，以及包括CTVT（犬传染性病毒性肿瘤）和MGT（乳腺肿瘤））的犬癌。 与良性组织相比，犬恶性肿瘤组织中KMO基因的表达水平上调。 此外，恶性肿瘤组织中KMO基因的表达水平高于非转移性肿瘤组织。 通过检测可疑组织标本中本发明生物标志物的表达水平，可以正确，快速地确定肿瘤组织的恶性。
-
7.发明申请CANINE TUMOR CELL AND ALLOGENEIC DENDRITIC CELL FUSED VACCINE AND METHOD FOR PREPARING THE SAME 有权犬肿瘤细胞和同种异体细胞融合疫苗及其制备方法公开(公告)号：US20100227395A1
公开(公告)日：2010-09-09
申请号：US12483735
申请日：2009-06-12
Applicant: Rea-Min Chu , Chien-Chun Pai , Tien-Fu Chuang
Inventor： Rea-Min Chu , Chien-Chun Pai , Tien-Fu Chuang
IPC: C12N5/16
CPC classification number: C12N5/16 , A61K39/001 , A61K39/0011 , A61K2039/5152 , A61K2039/5154
Abstract: The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived dendritic cells and canine tumor cells. The canine immune system can be induced to produce tumor specific T lymphocytes and natural killer cells when the fusion cells used as a vaccine is injected into a canine body.
Abstract translation: 本发明提供了通过融合犬肿瘤细胞和同种异体树突状细胞的基于树突状细胞的疫苗及其制备方法。 通过融合犬骨髓来源的树突状细胞和犬肿瘤细胞产生表达犬肿瘤抗原的融合细胞。 当用作疫苗的融合细胞注射到犬体内时，可以诱导犬免疫系统产生肿瘤特异性T淋巴细胞和天然杀伤细胞。
-
公开(公告)号：US07679749B2
公开(公告)日：2010-03-16
申请号：US12076203
申请日：2008-03-14
Applicant: Chii-Wann Lin , Jheng-Long Lee , Rong-Huay Juang , Shi-Ming Lin , Chih-Kung Lee , Rea-Min Chu , Ching-Ho Wang , Jim-Min Fang , Tsung-Liang Chuang
Inventor： Chii-Wann Lin , Jheng-Long Lee , Rong-Huay Juang , Shi-Ming Lin , Chih-Kung Lee , Rea-Min Chu , Ching-Ho Wang , Jim-Min Fang , Tsung-Liang Chuang
IPC: G01N21/55
CPC classification number: G01N21/553
Abstract: An optical waveguide SPR sensor is adapted for differential measurement. The optical waveguide SPR sensor includes a base, a bottom layer, and at least one set of optical waveguide layers. The set of the optical waveguide layers includes a measuring optical waveguide channel and a reference optical waveguide channel. The measuring optical waveguide channel includes an SPR sensing film layer. The measuring optical waveguide channel and the reference optical waveguide channel are independently configured and substantially parallel one to another. The bottom layer has a refractive index higher than a refractive index of the optical waveguide layer.
Abstract translation: 光波导SPR传感器适用于差分测量。 光波导SPR传感器包括基底，底层以及至少一组光波导层。 该组光波导层包括测量光波导通道和参考光波导通道。 测量光波导通道包括SPR感测膜层。 测量光波导通道和参考光波导通道独立地构造并基本上彼此平行。 底层的折射率高于光波导层的折射率。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.012 seconds)
